Patient access to new cancer drugs in the United States and Australia

Value in Health

Volumn 14, Issue 6, 2011, Pages 944-952

  Wilson, Andrew ^a   Cohen, Joshua ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

access to health care; Australia; cancer; pharmaceuticals; United States

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DASATINIB; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; OXALIPLATIN; PANITUMUMAB; PEMETREXED; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; AUSTRALIA; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; MEDICARE; NEOPLASM; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

ANTINEOPLASTIC AGENTS; AUSTRALIA; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; STATE MEDICINE; UNITED STATES;

EID: 80052760873     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.004     Document Type: Article

References (56)

1. N. Mulcahy Time to consider cost in evaluating cancer drugs in the US Medscape Medical News July 14, 2009 http://www.medscape.com/viewarticle/705689 [Accessed April 6, 2010]
2. Congressional Budget Office Research on the comparative effectiveness of medical treatments http://www.cbo.gov/ftpdocs/88xx/doc8891/12-18- ComparativeEffectiveness.pdf December 2007 [Accessed April 5, 2010]
3. P.J. Neumann Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers 2005 Oxford University Press New York
4. A. Mason, M. Drummond, and S. Ramsey Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 28 2010 3234 3238
5. T. Fojo, and C. Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 101 2009 1044 1048
6. J. Cohen, and W. Looney Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 102 2010 1207 author reply 120710
7. G.F. Anderson, U.E. Reinhardt, P.S. Hussey, and V. Petrosyan It's the prices, stupid: why the United States is so different from other countries Health Aff (Millwood) 22 2003 89 105 (Pubitemid 41388747)
8. J. Cohen, L. Faden, S. Predaris, and B. Young Patient access to pharmaceuticals: an international comparison Eur J Health Econ 8 2007 253 266 (Pubitemid 47231312)
9. P.M. Danzon, and M.F. Furukawa International prices and availability of pharmaceuticals in 2005 Health Aff (Millwood) 27 2008 221 233 (Pubitemid 351198606)
10. E.E. Roughead, R. Lopert, and L.N. Sansom Prices for innovative pharmaceuticals that provide health gain: a comparison between Australia and the United States Value Health 10 2007 514 520 (Pubitemid 350013269)
11. B.W. Breshnahan, P.J. Neumann, and R. Carlson Findings related to assessing value for private US health plans Am J Pharm Benefits 2 2010 219 227
12. D. Eddy Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis Health Aff (Millwood) 26 2007 500 515
13. S.J. Duckett Drug policy down under: Australia's pharmaceutical benefits scheme Health Care Financ Rev 25 2004 55 67 (Pubitemid 38725198)
14. R. Lopert, and S. Rosenbaum What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia J Law Med Ethics 35 2007 643 656
15. R. Lopert Evidence-based decision-making within Australia's Pharmaceutical Benefits Scheme (Issue Brief) The Commonwealth Fund Jul 2009 http://www.commonwealthfund.org/∼/media/Files/Publications/Issue%20Brief/ 2009/Jul/Chalkidou/1297-Lopert-CER-Australia-issue-brief-724.pdf [Accessed June 21, 2010]
16. D.J. Birkett, A.S. Mitchell, and P. McManus A cost-effectiveness approach to drug subsidy and pricing in Australia Health Aff (Millwood) 20 2001 104 114 (Pubitemid 33710304)
17. Australian Department of Health and Ageing Pharmaceutical Benefits Schedule Group Reports https://www.medicareaustralia.gov.au/statistics/pbs- group.shtml [Accessed December 9, 2010]
18. W.D. Hall, R. Ward, and W.S. Liauw Tailoring access to high cost, genetically targeted drugs Med J Aust 182 2005 607 608 (Pubitemid 40932327)
19. M. Tatchell Prescription pricing demystified Aust Prescriber 32 2009 6 8
20. K.E. Thorpe, and D. Howard Health insurance and spending among cancer patients Health Aff (Millwood) 2003 Jan-Jun(Suppl Web Exclusives): W3-18998
21. S.Y. Liang, J.S. Haas, and K.A. Phillips Medicare formulary coverage for top-selling biologics Nature Biotechnol 27 2009 1082 1084
22. US Food and Drug Administration NME Drug and New Biologic Approvals http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121136.htm [Accessed February 5, 2010]
23. Australian Department of Health and Ageing Therapeutic Goods Administration Australian Register of Therapeutic Goods http://www.tga.gov.au/ docs/html/artg.htm [Accessed February 5, 2010]
24. D.M. Gencarelli One pill, many prices: variation in prescription drug prices in selected government programs NHPF Issue Brief 2005 Aug 29;#807 http://www.nhpf.org/library/issue-briefs/IB807-DrugPricing-08-29-05.pdf [Accessed April 23, 2010]
25. Drug Topics Red Book 2009 2009 Thomson Reuters Montvale, NJ
26. Centers for Medicare and Medicaid Services April 2010 ASP Drug Pricing Files https://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/ downloads/April-2010-ASP-Pricing-File.zip [Accessed April 30, 2010]
27. Centers for Medicare and Medicaid Services Medicare Prescription Drug Plan Finder http://www.medicare.gov/MPDPF/Public/Include/DataSection/Questions/ MPDPFIntro.asp [Accessed April 30, 2010]
28. P. Moeller Top Medicare drug plan premium hikes US News & World Report http://www.usnews.com/money/blogs/the-best-life/2008/11/20/top-medicare- drug-plan-premium-hikes [Accessed September 11, 2009]
29. Australian Department of Health and Ageing Schedule of Pharmaceutical Benefits 2010 May 1 http://www.pbs.gov.au/publications/2010/2010-05-01-general- schedule.pdf [Accessed June 2, 2010]
30. Currency rates http://www.xe.com [Accessed April 30, 2009]
31. OECD Purchasing Power ParitiesParites de pouvoir d'Achat, Comparative Price LevelsNiveaux de prix compares 2006 OECD Paris
32. Centers for Medicare and Medicaid Services Medicare Coverage Database http://www.cms.gov/mcd/search.asp?clickon=search [Accessed May 20, 2010]
33. Australian Department of Health and Ageing PBAC Outcomes by Meeting http://www.health.gov.au/internet/main/publishing.nsf/Content/ pbac-outcomes-by-meeting [Accessed February 5, 2010]
34. Center for Medicare and Medicaid Services 2009 HCPCS Alpha-numeric file http://www.cms.hhs.gov/apps/ama/license.asp?file=/HCPCSReleaseCodeSets/ Downloads/09anweb.zip [Accessed February 5, 2010]
35. Medicare.gov MediGap (Supplemental Insurance) Policies http://www.medicare.gov/medigap/default.asp [Accessed April 16, 2010]
36. U.S. Government Accountability Office Medicare Part D: spending, beneficiary cost sharing, and cost-containment efforts for high-cost drugs eligible for a specialty tier 2010 Jan 29 http://www.gao.gov/products/GAO-10-242 [Accessed April 23, 2010]
37. Australian Department of Health and Ageing National Medicines Policy 2000 http://www.health.gov.au/internet/main/publishing.nsf/Content/ 1184A3544D5E9364CA2574FC0079DC1A/$File/nmp2000.pdf [Accessed February 5, 2010]
38. J.C. Robinson Insurers' strategies for managing the use and cost of biopharmaceuticals Health Aff (Millwood) 25 2006 1205 1217 (Pubitemid 44497619)
39. R.R. Faden, K. Chalkidou, and J. Appleby Expensive cancer drugs: a comparison between the United States and the United Kingdom Milbank Q 87 2009 789 819
40. Australian Department of Health and Ageing Therapeutic Goods Administration Regulation of therapeutic goods in Australia http://www.tga.gov. au/docs/html/tga/tgaginfo.htm 2005 Apr [Accessed December 1, 2010]
41. Australian Productivity Commission International pharmaceutical price differences: research report 2001 Jul http://www.pc.gov.au/projects/study/ pbsprices/docs/finalreport [Accessed April 2, 2010]
42. F.M. Clement, A. Harris, and J.J. Li Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada JAMA 302 2009 1437 1443
43. M.P. Coleman, M. Quaresma, and F. Berrino Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol 9 2008 730 756
44. National Comprehensive Cancer Network (NCCN) http://www.nccn.org [Accessed April 3, 2010]
45. J. Cohen, and A. Wilson New challenges to medicare beneficiary access to mAbs mAbs 1 2009 56 66
46. Singhealth Centre for Health Services Research Healthcare roundtable 8: formulary decision making process 2009 Jun 25 http://www.singhealth.com.sg/ Research/HealthServicesResearch/NewsEvents/PastEvents/Documents/ HSR%20Roundtable%20VIII%20Formulary%20Decision%20Making%20Process.pdf [Accessed March 2, 2010]
47. J. Cohen, A. Wilson, and L. Faden Off-label use reimbursement Food Drug Law J 64 2009 391 403
48. K. Chalkidou, S. Tunis, and R. Lopert Comparative effectiveness research and evidence-based health policy: experience from four countries Milbank Q 87 2009 339 367
49. G.C. Alexander, and R.S. Stafford Does comparative effectiveness have a comparative edge? JAMA 301 2009 2488 2490
50. D. Mechanic Muddling through elegantly: finding the proper balance in rationing Health Aff (Millwood) 16 1997 83 92
51. Cancer drugs emerging as top driver of specialty drug spending (news release) Medco Health Solutions http://phx.corporate-ir.net/phoenix.zhtml?c= 131268&p=irol-newsArticle&ID=1339933&highlight= 2009 Oct 8 [Accessed: December 17, 2009]
52. P. Neumann, J.A. Palmer, and N. Nadler Cancer therapy costs influence treatment: a national survey of oncologists Health Aff (Millwood) 29 2010 196 202
53. M. Drummond, B. Evans, and J. LeLorier Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology Can J Clin Pharmacol 16 2009 e273 e281 http://www.cjcp.ca/cjcp08040-macleod- e273-e281-r101758 [Accessed March 2, 2010]
54. J. Groopman Health care: who knows best? New York Review of Books 57 2010 12 15 http://www.nybooks.com/articles/23590 [Accessed January 11, 2010]
55. J.P. Cohen, and J.F. Bridges Assessing comparative effectiveness research in the US Appl Health Econ Health Policy 7 2009 219 224
56. J.P. Raferty Paying for costly pharmaceuticals: regulation of new drugs in Australia, England, and New Zealand Med J Aust 188 2007 26 28